Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03077165
Recruitment Status : Recruiting
First Posted : March 10, 2017
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Ilkos Therapeutic Inc.

Brief Summary:
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.

Condition or disease Intervention/treatment Phase
Venous Leg Ulcer Drug: S42909 100 mg Drug: S42909 200 mg Drug: S42909 400 mg Drug: S42909 800 mg Drug: S42909 1200 mg Drug: Placebo Oral Tablet Phase 2

Detailed Description:

S42909 is an inhibitor of β-Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase which also inhibits vascular leukocyte adhesion to endothelial cells, Matrix Metalloproteinase-2 (MMP-2) and Plasminogen Activator Inhibitor-1 (PAI-1) activity. It is proposed for development in the treatment of venous and mixed leg ulcers.

This proof of concept study is a randomized, double-blind, placebo-controlled, multicenter, Phase IIa trial to evaluate the dose response of S42909 for the treatment of venous leg ulcers.

Patients suffering from chronic venous disease and having at least one active venous leg ulcer will be selected at the selection visit (ASSE). One Reference Ulcer (RU) defined as the largest ulcer in size that is fitting the area selection criteria will be established. At ASSE, a first picture will be taken before cleansing and debridement and a second picture will be taken after cleansing and debridement. The investigator will check that the selection RU area is compliant with the selection criteria. Patients will start the selection period and will be switched from their current pharmacological and/or local treatment (if any) for venous leg ulcer to local wound care with sterile saline solution or sterile water, "non-active" dressings and standardized compression (same strength and type of compression). They will be administrated the placebo selection treatment for a period of fourteen days.

Three (or four) working days before the inclusion visit, the participants will come to the site for a RU picture in order to get the RU area central measurement for inclusion visit (W000).

At W000, the investigator will check that the inclusion RU area is compliant with the inclusion criteria. The investigator will also check that the participant is compliant with the selection treatment and stockings wearing.

All participants found to be eligible for inclusion will be randomized to one of the following six groups - S42909: 100, 200, 400, 800 or 1200 mg per day- or placebo.

The participants will enter a 6 weeks ambulatory Investigational Medicinal Product (IMP) treatment period on top of standard of care (standardized compression and local wound care with sterile saline solution or sterile water and "non-active" dressing) followed by a 2 weeks follow-up period of standard of care only. During this period the participants will return to the investigator's site for intermediate visits after one week (W001), two weeks (W002), three weeks (W003), four weeks (W004), six weeks (W006) and eight weeks (W008). Participants will continue receiving standardized compression therapy and local wound care (sterile saline solution or sterile water and "non-active" dressing) until the end of the study (W008).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 204 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.
Actual Study Start Date : September 12, 2017
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A
S42909 dose 100 mg p.o., 50 mg bid
Drug: S42909 100 mg
50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Experimental: Group B
S42909 dose 200 mg p.o., 100 mg bid
Drug: S42909 200 mg
50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Experimental: Group C
S42909 dose 400 mg p.o., 200 mg bid
Drug: S42909 400 mg
200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Experimental: Group D
S42909 dose 800 mg p.o., 400 mg bid
Drug: S42909 800 mg
200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.

Experimental: Group E
S42909 dose 1200 mg p.o., 600 mg bid
Drug: S42909 1200 mg
200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Placebo Comparator: Group F
Placebo p.o. bid
Drug: Placebo Oral Tablet
Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.




Primary Outcome Measures :
  1. Relative reduction of Reference Ulcer area after 4 weeks of treatment on top of standard of care compared with baseline Reference Ulcer area (W000) assessed during study visits [ Time Frame: Week 4 ]
    Compared with baseline Reference Ulcer area (W000) assessed during study visits


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Up to 8 weeks ]
    Occurring during the double-blind period of the study

  2. Assessment of laboratory parameters [ Time Frame: Up to 8 weeks ]
    Biochemistry, Haematology and Fasting Lipids



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Caucasian (defined for this study as having 2 Caucasian parents), men or women
  • Age ≥ 18 years old
  • 18.5 kg/m2 ≤ BMI ≤ 45.0 kg/m2 (= Weight (kg) / height² (m²))
  • Patients with chronic venous disease documented by imaging to detect a venous disorder in one or both the sub- and extra-fascial venous systems. The examination performed within 6 months before selection can be used.
  • Patients with at least one active venous leg ulcer localised in the gaiter area (CEAP C6) diagnosed or reoccurred for more than 6 weeks and less than 2 years at selection and 3 cm away from other ulcers. Patients with bilateral ulcerations or multiple ulcerations on one or both legs are eligible for selection.
  • Size of Reference Ulcer (defined as the largest ulcer in size that is fitting the area selection criteria) should be ≥ 5 cm2 and ≤ 100 cm2 at the selection visit and ≥ 4.5 cm2 and ≤ 100 cm2 at the inclusion visit (measured by transparent sheet and confirmed with the digital 3D imaging device).
  • Ankle Brachial Pressure Index (ABPI) ≥ 0.8 and ≤ 1.3 measured by Doppler ultrasound.

Exclusion Criteria:

  • Unlikely or unwilling to be compliant to standardized compression recommendation, study medication and visits, previous records of poor compliance to compression stockings.
  • Inadequately controlled type 1 and type 2 diabetes with an HbA1c > 8%.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03077165


Contacts
Layout table for location contacts
Contact: Monique Champagne, BPharm, MSc 450-680-3381 ext 2910 mchampagne@ilkostherapeutic.com

  Show 62 Study Locations
Sponsors and Collaborators
Ilkos Therapeutic Inc.
Investigators
Layout table for investigator information
Principal Investigator: Eberhard Rabe, Professor Department of Dermatology University of Bonn

Layout table for additonal information
Responsible Party: Ilkos Therapeutic Inc.
ClinicalTrials.gov Identifier: NCT03077165     History of Changes
Other Study ID Numbers: CL2-42909-016
First Posted: March 10, 2017    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Ulcer
Leg Ulcer
Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases